Please assess the completion status of the following clinical trial:

Trial Title: Belatacept to Prevent Organ Rejection in Kidney Transplant Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Receiving first renal (e.g., kidney) transplant~* Transplant is from a non-HLA-identical living donor~* Willing to use acceptable forms of contraception~Exclusion Criteria:~* Positive for anti-human globulin (AHG) or T-cell cross-match with the donor~* Receiving multiple-organ transplant~* History of cancer within the 5 years prior to study entry. Patients who have certain nonmelanoma skin cancers are not excluded~* Human immunodeficiency virus (HIV) infected~* Hepatitis B (HBV) or C (HCV) virus infected~* Other active infections~* Active tuberculosis (TB) infection within the 3 years prior to study entry~* Pregnancy or breastfeeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Belatacept (Type: EXPERIMENTAL): Immunosuppressive protocol consisting of belatacept, glucocorticoids, antithymocyte globulin (ATG), and sirolimus.

Based on this trial design, predict the completion outcome and termination type (if applicable).